Abstract-Low temperature plasma (LTP) has emerged in the last decade as a novel and promising therapy for wound and skin decontamination, promotion of wound healing, cancer remission, control of wound-resident multidrug resistant bacteria, and dental and cosmetic applications, among others. Progress has been rapid in developing clinically useful devices and many studies are underway worldwide. Mechanisms of plasma therapeutics are beginning to be understood but much remains to be explored. This review focuses on mechanisms coupling the physics and chemistry of LTPs to medically relevant biochemistry and biology.
I. INTRODUCTION

L
OW TEMPERATURE plasmas (LTPs) have been explored for biological and medical applications for decades. The early uses relied mainly on thermal effects for electro-surgery including tissue cauterization and blood coagulation. The history of using plasma devices as a thermal scalpel is described by Glover et al. [1] . More recently, commercial surgical devices using plasma created in aqueous saline solution and argon jet plasmas are representative of this class of widely used surgical technology [2] , [3] .
Low pressure plasma experiments were conducted in the 1960s and 1970s for biological applications. For example, oxygen plasma was investigated by NASA with an aim to destroy biological matter and inactivate microorganisms for space applications [4] , [93] . This was followed by in-depth investigations to evaluate the potential of using low pressure plasmas for sterilization of heat-sensitive medical tools [5] .
In the mid-1990s experiments were conducted that showed the nonthermal atmospheric pressure plasmas can be used to inactivate bacteria on both biotic and abiotic surfaces [6] . By the early 2000s, a series of reports were published on the use of atmospheric pressure LTP altering mammalian cells without causing necrosis and under some conditions even leading to apoptosis (programmed cell death) [7] - [9] . The first LTP sources were approved for clinical testing (i.e., received "CE certification" in the European Union) in 2013. The "kINPen MED" (neoplas tools GmbH, Greifswald, Germany) is an RF powered (1 MHz) Ar jet. The "MicroPlasSter" (ADTEC, Hunslow, U.K.) is a microwave (2.45 GHz) powered Ar-plasma torch. Both devices are operated in such a way that there is no significant thermal heating of treated tissue. The "PlasmaDerm" device (CINOGY GmbH Duderstadt, Germany) operates as a dielectric barrier discharge in open air and is also nonthermal. More detailed descriptions of these and other plasma medical devices can be found in [10] and [11] .
A few human clinical tests have been reported for wound healing and cancer treatment [12] - [15] . Fig. 1 illustrates one recent clinical application of plasma to a patient suffering from head and neck cancer [16] . The patient shown in Fig. 1 first had surgery for his squamous cell carcinoma of the oral cavity, but a subsequent scan showed the tumor had partially infiltrated the vascular wall of the external carotid artery, making additional surgery impossible. The patient then underwent radiation and chemotherapy. The tumor wound was found to be bacterially contaminated. The patient's carotid artery prevented normal wound care, so palliative cancer treatment using plasma was initiated with the patient's consent. The kINPen MED (R) was used every two to three days with an exposure protocol of 1 min/cm 2 treatment, with the jet moved across the tumor surface with a 1 cm separation between the jet and the surface. The plasma was effective in reducing tumor bacterial decontamination as well as reducing tumor mass, as can 2469-7311 c 2017 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission.
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be seen in Fig. 1(a) -(c). The observed plasma-induced tumor regression is promising, but the tumor growth could resume.
No plasma-induced side effects were reported. The steps needed to develop a new medical technology are listed in Fig. 2 . Application of the U.S. Agency for Health Care Policy and Research classification system places plasma medicine somewhere near evidence-based medicine (EBM) stage IV: consent of experts. The next level calls for pilot studies, and these are just beginning as noted in the case described in Fig. 1 (see [17] ). The trajectory of a new medical technology can be relatively long before widespread clinical use, but the progress of plasma medicine has been encouraging to date. Nevertheless, it will probably be more than a decade before large-scale randomized clinical trials and the subsequent systematic reviews are completed.
Other "physical" technologies that eventually became medical technologies can provide some perspective on the sometimes relatively long transition to clinical acceptance. For example, the therapeutic application of pulsed electric fields (PEFs) to transiently permeabilize the cell membrane of tumors promoting uptake of anti-cancer drugs began with initial Phase I-II clinical trials first reported in about 1993 [18] . This method, referred to as "electro-chemotherapy" has been a notable success for cutaneous and some subcutaneous tumor treatments and is now in widespread clinical use, especially in Europe and parts of Asia. We might expect a similar, relatively long period of time needed to develop the many applications of plasma medical therapeutics.
This review is primarily concerned with assessing the current state of understanding mechanisms of plasma medicine-a field that combines plasma physics and biology. Plasma physics and biology are different fields. These differences tend to compromise communication between specialists in the different areas that comprise the field. Biologists, biochemists, and plasma physicists and chemists must come to some mutual understanding in identifying pathways to establish mechanisms.
Mechanistic understanding is far less well developed for LTPs operated at atmospheric pressure compared to low pressure operation as applied to surface treatments, etching, and film deposition, etc. Furthermore, when LTP is in contact with liquids, drops, or aerosols, understanding is even less well developed. The latter case is the one that is associated with plasma medicine.
The complexities of atmospheric plasma interacting with nonliving liquids or solid surfaces are relatively simple compared to the challenges of understanding how LTP interacts with cells, tissues, and organisms. Here, the gap between physics and biology becomes apparent. This gap manifests itself in part by terminology and nomenclature. But the differences between these fields is deeper than word definitions. Every scientific field must define the nature of "proper" questions and the nature of proper answers to these questions. Ball observes that physics is "... a way of thinking about the world: a scheme that organizes cause and effect" [19] . Physics is mathematical and reductive. In this view, nature is best understood by simplifying the system under study, isolating and focusing on understanding individual forces and components. The goal is to arrive at universal, mathematically formulated physical laws or principles that can be validated in the laboratory.
Biology, by contrast, developed as a descriptive field. Furthermore, biology seems easiest to understand only if it is assumed that the living system under study has a "purpose" [19] , [20] . Living systems normally "want" to survive and reproduce, transmitting their genetic characteristics, perhaps slightly modified, to progeny. Purpose is not a helpful postulate in physics.
Dobzhansky [21] famously observed "Nothing in Biology Makes Sense Except in the Light of Evolution". Darwinian evolution is descriptive, not expressed in a mathematical form. Its power and centrality in biology cannot be denied (at least scientifically), but in its current form it is neither functionally nor conceptually equivalent to mechanics or electromagnetism or any other area of physical science. It represents an entirely different "scheme that organizes cause and effect." Recent progress in unifying at least some aspects of the two fields seems promising [22] . A genuine integration will eventually emerge, but it is not certain when or how this will affect a field like plasma biomedicine.
The best approach when trying to combine elements of physics and biology, given our current knowledge, is perhaps to immerse oneself in each of the two cultures as much as possible. It requires patience, effort and time to even approach some level of understanding of both fields. This paper attempts to briefly survey the status of understanding of how the fields interact in the context of mechanisms of plasma medicine.
II. MECHANISMS OF PLASMA MEDICINE
The main thrust of this review is to present some of the evidence currently available concerning the physical and chemical phenomena associated with LTP application to living tissue that could possibly lead to the observed therapeutic effects. The primary focus will be on applications in tissue disinfection, wound healing, and tumor treatments. Most of the ideas presented here have been presented before-usually in the open literature, including previous reviews. However, the field is changing rapidly on all fronts and the "big picture" is constantly evolving. The physics and chemistry of the commonly used plasma devices are becoming better understood, and the biological responses associated with treatment have multiplied in the last several years as well. In some cases, previously unknown or poorly understood connections to related fields of research have been established or clarified. The emphasis in this paper is on the elements that are relatively new and that has not been incorporated into previous reviews, although there is some inevitable overlap.
The first mechanistic topic covered will be the role of reactive oxygen and nitrogen species (RONS). Various aspects of the relation between RONS and possible therapeutic mechanisms have been presented before, e.g., [23] - [26] -and in some detail, but there are new and important aspects that will be described in this section. The relationship between LTP medical therapies and related therapies that involve RONS will be described. These include cancer treatments involving radiation, photodynamic therapy, and many chemotherapies.
The second plasma medicine mechanistic topic will be the role of PEFs created by plasma at tissue surfaces. Because of the success and progress in understanding the use of PEFs for electro-chemotherapy, transdermal drug delivery, irreversible electroporation, and gene transfection, we can make educated guesses about what plasma-generated PEFs might be doing.
The third topic covered will be the use of plasma-activated medium (PAM). In the last several years, considerable evidence has accumulated that shows that treating cell culture medium with plasma can generate a relatively long-lasting solution that can be subsequently applied to tissue, cavities, or tumors with impressive effects. Since cell culture medium is often complex, with many dozens of compounds, it has been difficult to know what precisely LTP exposure is doing to the solution. This area overlaps most directly with the field of plasma-liquid interactions, another rapidly developing field.
Finally, LTPs have been shown recently to have nonlocal effects when applied to organisms. Subcutaneous blood flow and blood O 2 content can be significantly increased following plasma exposure. This could have profound effects and the results indirectly suggest some potential mechanisms. Another recent focus is the nonlocal effect of LTP on stimulating innate and adaptive immune responses. It is perhaps not surprising that apparently similar adaptive immune stimulation has been observed for many years in existing therapies, including in radiation therapy, photodynamic therapy, and PEF electrochemotherapy, among others. It seems likely that the observed overlap between these methods can be exploited to deepen our understanding of all of them.
III. REACTIVE OXYGEN AND NITROGEN SPECIES
Some biologically common RONS are listed in Table I (a)-(c). Table I (a) lists reactive oxygen species (ROS), Table I (b) lists reactive nitrogen species (RNS) and Table I (c) lists reactive halogen species (RHS). Many of these biologically generated species are also created in plasma or in water adjacent to plasma. Not shown here are other reactive species such as reactive sulphur species and the carbon-based radicals, or peroxyl compounds that are created when radicals such as OH abstract an H atom from a hydrocarbon molecule followed by O 2 addition. The logic behind the association between plasma medicine and RONS as active agents is simple: RONS are created in large concentration in plasma chemical processes, they are readily transferred to adjacent aqueous liquid phases (including, e.g., cells and tissues) and they are known to play many important biological roles. The presumption is that chemical species delivered to tissue will function analogously to species created endogenously (i.e., by the cells/organisms themselves). Of course, there are serious questions about how externally generated species will transport and affect internal processes. This topic is addressed later but it is a crucially important problem that has only just begun to be considered by the plasma biomedicine research community.
As noted in Chemical reactions involving RONS are usually categorized as involving the transfer of an electron, also known as oxidation-reduction ("redox") reactions. For example, O 2 will "grab" electrons from other, less electronegative species, thus increasing the "oxidation state" of the partner. Losing an electron means the species has been oxidized, thus increasing the oxidation state. Conversely, gaining an electron means the species has been reduced. The oxidation state of the species reflects this idea: e.g., Fe 2+ (ferrous ion) is reduced compared to Fe 3+ (ferric ion). These species are important because they can participate in forming OH radical in what is termed Fenton chemistry. The Fenton reaction in the presence of Fe 3+ (illustrated in Fig. 3 are all known to be created in the gas phase and in water adjacent to plasma, e.g., [27] - [31] . Winter et al. [28] showed that plasma generated H 2 O 2 concentration in cell culture medium correlated most strongly with the viability of human skin cells. Wu et al. [32] identified 1 O 2 (singlet delta O 2 or SDO) in plasma-treated aqueous solution. These authors reported that SDO appeared to be the dominant anti-bacterial component of the solution in their measurements. Hefny et al. [33] reported that O atoms can play the central oxidizing role in solutions exposed to O-containing plasmas. This is noteworthy in the present discussion because O atoms appear to be one ROS that is not generated via a natural cellular process.
RHS such as OCl − are known to play key roles, for example, in innate immunity (see below). But these species are only beginning to be addressed in the plasma-liquid literature. The first tentative identification of plasma-generated OCl − (in aqueous solution containing chloride ions) was apparently from Wende et al. [34] .
Of the RNS, NO is undoubtedly the most important. NO, a free radical gas, is now known to be an important intracellular messenger molecule that activates the soluble guanylyl cyclase at nanomolar concentrations [35] . Guanylyl cyclase is responsible for converting guanosine triphosphate to cyclic GMP, which causes smooth muscle relaxation. Prior to 1980, NO, which is present in automobile exhaust and cigarette smoke, was considered only as an environmental pollutant.
This view of NO changed in the 1980s when Robert Furchgott discovered that the endothelium released a labile factor, termed endothelial-derived relaxing factor (EDRF), which caused vascular relaxation when vascular smooth muscle cell preparations were stimulated with vasodilators (e.g., acetylcholine, histamine, and bradykinin). EDRF was also called "nitrovasodilator" because nitrovasodilators such as nitroglycerin, nitroprusside, other organic nitrites, cause vascular relaxation. Ignarro, Furchgott, and Murad proposed that EDRF is NO and they received the Nobel Prize in Physiology/Medicine in 1998 for this important discovery.
Since this original discovery through the end of the last century, research on the biological and biomedical implications of NO (and related compounds) has exploded. This compound is particularly interesting in the context of plasma medicine because of its powerful range of biological functionality coupled with the fact that it can be produced in considerable quantities in LTP with O 2 and N 2 present-including of course, in air. Another important compound that is invariably present in water adjacent to air plasma is the nitrite anion NO − 2 . It is well documented that nitrite has a wide range of therapeutic applications [36] . In part, this is because NO − 2 can act as a kind NO reservoir, releasing NO when local pH becomes sufficiently acidic [37] . Furthermore, NO − 2 in the presence of H 2 O 2 either under acidic conditions or in the presence of UVA photons, will also decompose and is observed to be strongly antimicrobial [38] .
Early reports of plasma medical applications noted the creation of NO [39] . Some plasma devices are thought to operate specifically by creating significant fluxes of NO [40] . The role of NO generation in plasma medical devices was recently reviewed [41] . There has been a considerable effort in developing various therapeutic NO donors-either through compounds that decompose to form NO or some other mechanism [42] , [43] . In the context of plasma medicine, the well known role of NO in wound healing and its antimicrobial role are usually emphasized. But there is also increasing interest in NO and related compounds for its anti-cancer applications [44] , [45] . Fig. 4 . Top level lists the sources of RONS in biological systems, to which we might add plasma to the "exogenous" sources. The upper center box shows "antioxidant defenses" that are used to limit RONS concentration. There is a dual nature of RONS: too few and the result is impaired physiological function; the right amount leads to "homeostasis" (the ideal state); but too much leads to aging, disease and cell death. Following Krumova and Cosa [46] .
A. "Goldilock" Compounds: Too Little or Too Much Is Bad
The situation with respect to RONS is complex, however. Fig. 4 illustrates a typical summary. Endogenous (internal to the organism) sources of RONS include various enzymatic reactions. Exogenous sources (to which "plasma" could be added here) can also result in RONS creation. In either case, various enzymatic and nonenzymatic "anti-oxidant defences" are present to manage the proper concentrations. As noted in Fig. 4 , "impaired physiological function" follows from either too low or too high a rate of RONS production.
The complexity of the role of NO and related reactive nitrogen compounds, and this is reflected in other reactive species as well, is captured by the following quote from the review of Dedon and Tannenbaum [47] on the relation between inflammation and cancer.
"The preponderance of epidemiological evidence now points to a strong association between chronic inflammation and cancers of several organs, including the gastrointestinal tract, liver, and lungs. The strongest evidence for a mechanistic link here involves the generation of RONS by macrophages and neutrophils that respond to cytokines and other signaling processes arising at sites of inflammation. These reactive species cause oxidation, nitration, halogenation, RONS naturally produced by white blood cells (leukocytes) neutrophils and macrophages. Following Dedon and Tannenbaum [47] .
and deamination of biomolecules of all types, including lipids, proteins, carbohydrates, and nucleic acids, with the formation of toxic and mutagenic products."
Clearly, inflammation that is not resolved fairly quickly can lead to problems such as cancer. But inflammation and innate immunity are also very important in the body's self-defence as well. Fig. 5 illustrates some of the RONS chemistry generated by macrophages and neutrophils, white blood cells that respond via the innate immune system to tissue damage, infection, and tumors [47] . This figure also illustrates some of the potentially damaging reactions that can occur between the RONS created by while blood cells and cellular DNA and other proteins. It is remarkable that N 2 and O 2 containing plasma will generate many of the same species in water adjacent to the plasma. The innate immune system is mostly responsible for responding to tissue damage, infection, and tumors. These are all important applications of plasma for therapy, and the current working hypothesis of plasma medicine investigators is that these facts are related.
B. Role of RONS in Nonplasma Therapies
One of the most promising approaches in developing a rational basis for understanding and exploiting plasma medicial therapies is in identifying how plasma biological and therapeutic effects overlap with existing therapies. This is a recurring theme in this review, but what about the case for therapies associated with RONS in existing therapies? One of the most prominent examples concerns cancer therapies. In the last several years, there have been multiple studies that point out the connection between RONS and cancer therapeutics [48] . For example, Watson writes the following:
"The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle....A common ROS-mediated way through which almost all anti-cancer agents induce apoptosis explains why cancers that become resistant to chemotherapeutic control become equally resistant to ionizing radiotherapy" [49] .
With respect to developing tumor radio-resistance, Diehn et al. [50] pointed out that cancer stem cell resistance to radiation is associated with higher levels of antioxidants and lower levels of cellular ROS. Gorrini et al. [51] listed many anti-cancer drugs that act either to directly increase ROS levels in tumors or indirectly by reducing anti-oxidant metabolism. Piskounova et al. [52] recently showed that ROS and oxidative stress can act to minimize tumor metastasis.
The importance of RONS in various therapies is well established and the fact that plasma creates copious quantities of these species in the gas phase is uncontested. Furthermore, many plasma medicine investigators have shown, at least indirectly, that plasma effects are connected to RONS [53] , [54] .
But how do the gas phase specie enter tissue and have an effect beyond the surface? Most of the species generated in the gas phase are highly reactive and would be expected to penetrate only a short distance before reacting. Numerous researchers are beginning to investigate this question (e.g., Oh et al. [55] ), but it will be a key focus of research no doubt for many years.
Indeed, a central aspect of postulating mechanisms for plasma biomedicine is explaining how a surface-active process like plasma exposure can generate a response over much longer time-and length-scales than the original exposure. It would seem that plasma must trigger a biological response that propagates in time and space from the original exposure. In Fig. 1 , as noted above, the patient was treated with a plasma jet with exposures of about 1 min/cm 2 of tissue, three times per week for about four months. What could possibly explain the observed response? It would seem that there must be some kind of cell-to-cell communication process that links processes at tissue surfaces where the plasma exposure occurs and deeper levels of tissue. This key question is addressed in the following section.
C. Models of Cell-Cell Communication Induced by Plasma Therapies
One possible way that surface plasma exposure could trigger RONS-mediated cell-to-cell communication is via cellular reactive species generation. For example, Zorov et al. [56] described a process in which ROS generated either inside or outside the cell can induce the release of additional ROS via mitochondrial mechanisms. These authors term this process ROS-Induced ROS Release or RIRR.
A related phenomenon appears to be associated with ionizing radiation (IR) exposure. It is widely accepted now that the effects of IR is mediated by a cell-to-cell communica-tion process referred to as the "bystander effect" [57] , [58] . Although plasma therapies are unlikely to involve iden-tical mechanisms, the model proposed, for example, by Havaki et al. [58] has some attractive features. Fig. 6 (reproduced from Havaki et al. [58] ), summarizes the role of cytokines and RONS in mediating bystander effects in both adjacent (via gap junctions) and more distant cells. The key point is that RONS are important in transmitting the signals, so even if the originating RONS are plasma-generated, the subsequent cell stress signaling might be similar.
In a sense, we can think of plasma-generated RONS as simulating natural cellular responses, since the same species can be dissolved or created in water adjacent to plasma. But these examples show that plasma-generated RONS can also stimulate more RONS generation.
Another recently proposed model for how plasma might selectively induce cancer cell apoptosis is described by Bauer and Graves [26] . These authors postulate that singlet delta O 2 ( 1 O 2 or "SDO") might play a key role, as illustrated in Fig. 7 .
The postulated self-propagating mechanism described in Fig. 7 begins with plasma-generated SDO, inactivating cancer cell membrane bound catalase. Catalase enzymes convert H 2 O 2 to water, among other roles. Precancerous, or "transformed" cells create these protective enzymes to disable natural intercellular cell signaling leading to apoptosis. These cancer cell protecting enzymes are a natural target for anticancer therapies. By eliminating catalase, the "extra" hydrogen peroxide (H 2 O 2 ) reacts with peroxynitrite (ONOO − ), leading to additional SDO in a self-propagating process. In addition, chemical reactions between cancer cell-generated O 2 − and other RONS species (e.g., OCl − and NO), ultimately leads to cancer cell apoptosis.
IV. PLASMA-ACTIVATED MEDIUM
As noted by Weltmann and von Woedtke [11] , in biological interactions, gas phase species must generally interact The net effect result is intracellular RONS and cytokine production. RONS generated in the bystander cells can alter mitochondria, thus generating more RONS that are released. If a cell has enough DNA damage, apoptosis results in release of oxidized extra-cellular DNA, another signaling compound, thereby extending the cycle. In the context of plasma medicine, this RONS-and cytokine-mediated stress response offers a potential model of how the plasma can transmit its effects to distant cells. Following Havaki et al. [58] . Fig. 7 . Proposed schematic model of role of cold atmospheric plasma in selective cancer cell treatment. Cold atmospheric plasma generates 1 O 2 , leading to inactivation of tumor cell membrane-bound catalase. In the absence of these protective catalase enzymes, a self-replicating mechanism generating more 1 O 2 is postulated. Following Bauer and Graves [26] .
with liquids before being biologically active since cells consist mostly of water. A relatively recent development in plasma medicine is the discovery that plasma-treating cell culture medium generate therapeutically active liquid mixtures, sometimes referred to as PAM [59] , [60] or plasma stimulated medium (PSM) [61] . The mechanisms associated with PAM are not generally well understood, in part because plasma-liquid interactions even for simple liquids like water, and cell culture media are much more complex. What the plasma is doing to the cell culture medium is generally poorly understood.
However, recent research reveals that hydrogen peroxide (H 2 O 2 ) and nitrite (NO − 2 ) are probably important compounds in PAM created by the plasma [59] . Furthermore, Tanaka et al. [60] identified lactate as the key anticancer compound in PAM using Ringer's solution. And Yan et al. [61] showed evidence that aquaporins in cancer cell walls that promote transport of H 2 O 2 into cells is a key anti-glioblastoma mechanism in their studies of the mechanisms of PSM. The use of plasma treated medium for various therapeutic applications is clearly promising. In part this is due to the fact that medium can be stored for later use. Mohades et al. [62] reported data showing how the biological effects of PAM correlate with the concentration of H 2 O 2 in the treated medium.
Also, a liquid can be applied conveniently to large areas, or can be used for difficult-to-treat regions such as tumors that might coat interior cavities, such as the peritoneal cavity in ovarian cancer [63] .
V. PULSED ELECTRIC FIELDS AND CELLULAR ELECTROPORATION
It has been known since the 1940s that the electrical conductivity of cell membranes can be electrically modified [64] . Fig. 10 . Measured E-field during one pulse at different axial positions (see Fig. 9 ) in a He discharge. The voltage pulse is shown for reference. Following Robert et al. [73] . Fig. 11 . Averaged results from ten treatments on five mice. Five minute He jet LTP application to mouse skin increases subcutaneous O2 content (top) and blood flow (bottom). Effects are confined to location of LTP jet application. Following Collet et al. [79] .
Investigations into the biomedical applications of cell electroporation accelerated in the 1990s (e.g., [65] and [66] ) Fig. 8 is a schematic illustration of the various ways that PEFs lead to electroporation and various applications. The electric fields needed to electroporate cell membranes are typically on the order of 1-10 kV/cm and pulse lengths range from a few tens of nanoseconds to milliseconds depending on the application. For example, electrochemotherapy utilizes PEFs to permeabilize cell membranes in order to promote transfer of chemotherapeutic drugs into the tumor, as seen in Fig. 8(b) [67] . Gene transfection can also be induced [ Fig. 8(c)] , and if the pulses are strong and frequent enough, irreversible electroporation occurs [ Fig. 8(d) ] [67] - [69] .
There are now a series of studies that show that the transient electric fields formed at surfaces exposed to atmospheric pressure plasma jets are on the same order as the electric Fig. 12 . Ionizing radiation-induced ICD: endoplasmic reticulum stress leads to apoptotic release of damage-associated molecular patterns such as ATP ("find-me" signal) and membrane blebs with the CRT/ERp57 complex ("eat-me" signal). Antigens created following death of the tumor cells are taken up by dendritic cells, leading to cytotoxic lymphocyte (T-cell) activation. These cells then act against tumors displaying similar antigens, thoughout the body. Following Reynders et al. [91] . fields used in the electroporation applications sketched in Fig. 8 , e.g., [70] - [72] . For example, Robert et al. [73] and Darny et al. [74] reported electric fields at surfaces exposed to atmospheric pressure rare gas jets, one example of which is shown in Figs. 9 and 10 [73] .
The magnitudes of both the longitudinal (E x ) and radial (E r ) electric fields-about 1-10 kV/cm-are on the same order as those responsible for the effects illustrated in Fig. 8 . Furthermore, numerous authors report plasma-aided gene transfection and/or transdermal drug delivery [75] - [77] . Interestingly, Xu et al. [78] provided evidence that reactive species may enhance membrane poration induced by the plasma-generated electric field effects [78] .
VI. NONLOCAL EFFECTS: LTP STIMULATION
OF SUBCUTANEOUS BLOOD FLOW AND BLOOD O 2 CONTENT Several authors have reported that application of a rare gas plasma jet or air DBD can lead to a substantial increase in local blood flow and blood O 2 content. The first report was from Collet et al. [79] (see Fig. 11 ). These authors applied a He plasma jet to the skin of five mice and measured the effects on tissue oxygen partial pressure (pO 2 ) using a timeresolved luminescence-based optical probe. Blood flow was measured using a laser Doppler technique. Remarkably, following LTP treatment of the skin, pO 2 increased rapidly. This effect was correlated with the blood flow increase. The LTP alterations to blood flow and O 2 content were localized to the point of application, and the perturbations were relatively long lasting-in some cases, up to several hours. Similar effects were reported by Huerer et al. [80] and Kisch et al. [81] , [82] in studies involving human volunteers. These reports of the effects on human skin are similar to the results of Collet et al. on mice skin: the effects are confined locally to the point of application of the plasma and the effects can last on the order of an hour.
The therapeutic significance of these results on subcutneous blood flow and O 2 content are not completely clear at present. It is suspected that these LTP-induced alterations are related in NO or NO x products such as nitrite, species that have been shown to have similar effects on blood flow [41] . It is wellknown that hypoxia (reduced level of tissue O 2 ) is common in both wounds and tumors and is known to be therapeutically significant, so of course this clear LTP-induced effect on blood flow and O 2 needs further study [83] - [85] .
VII. NONLOCAL EFFECTS: STIMULATION
OF IMMUNE SYSTEM The second major nonlocal effect induced by LTP is stimulation or modulation of the immune system. The mammalian immune system consists of two parts: 1) the "innate immune system" that responds rapidly, via an inflammatory response, to tissue damage, infection and tumor detection and 2) the "adaptive immune system" that is able to target antigen-specific targets with a kind of "immunological memory."
As noted above, LTP is thought to mimic or simulate some aspects of at least innate immunity through its extensive use of RONS [86] , [87] . There is also growing evidence of the role of RONS in regulating some aspects of adaptive immunity as well [88] . The main purpose of this section is to identify LTP as a possible path to adaptive immunity stimulation, especially in the context of cancer therapy. Miller et al. [89] recently showed that LTP might act to induce immunogenic cell death (ICD), thereby stimulating an adaptive immune response to attack tumors [89] .
In fact, many of the physical methods used to treat tumors, including IR therapy, photodynamic therapy, electrochemotherapy, high hydrostatic pressure, ultraviolet C radiation, and hyperthermia have been reported to stimulate ICD and a subsequent adaptive immune response [66] , [90] . It is therefore perhaps not too surprising that LTP is reported to play a similar role. Fig. 12 illustrates the idea in the context of IR therapy, but the same idea holds for all of the other coupled immunology therapies listed above [91] . Direct, local treatment of the tumor by IR leads to local tumor death and the creation of antigens that are taken up by dendritic cells, leading to T-cell activation and subsequent attack of tumors throughout the body. A 2016 paper reports many ongoing clinical trials coupling IR therapy and immunotherapy [92] .
It is too soon to comment on how LTP therapy will compare with the other immune-stimulating modalities, but the wide range of operating conditions and physico-chemical effects, coupled with the relative ease in delivering plasma to desired location suggests that LTP will be a leading contender for these applications in the future.
VIII. CONCLUSION
This relatively brief summary of the mechanisms likely to be involved in plasma medical applications has emphasized the various physical and chemical phenomena that are known to occur with LTP coupled with their known or suspected biomedical effects. Reactive oxygen and nitrogen, PEFs, and the effects associated with PAM are currently the leading contenders for "important mechanisms." These phenomena are thought to trigger both local and nonlocal biological effects. The nonlocal effects associated with blood flow and blood O 2 content as well as effects on the immune system are especially promising for future medical applications. The biomedical effects with LTP devices are in some ways similar to effects observed with other therapies such as IR, photoninduced effects and PEFs and this connection is not surprising given the known similarities of LTP devices and the previous technologies.
A great deal of relevant research and many important publications were, of necessity, left out of this short review. The field is in a rapid phase of growth and change and we expect to see continuing progress over the coming years.
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